Home > Business > PTI > Report

Ranbaxy gets FDA nod for Isotretinoin capsules

June 23, 2003 16:15 IST

Ranbaxy Laboratories on Monday said it has received the US Food and Drug Administration's approval to manufacture and market Isotretinoin capsules, a generic version of Hoffman LaRoche's Accutane.

The company, which is the first to receive FDA for the Isotretinoin capsules of 30 mg, will market it under the name 'Sotret' by its subsidiary Ranbaxy Pharmaceuticals Inc.

The capsules are indicated for recalcitrant nodular acne and the overall sales of the drug stood at $415 million, a company release said in New Delhi.


Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor



Related Stories


Ranbaxy down on Mohali fire

Ranbaxy gets USFDA nod for drug

Ranbaxy up on USFDA nod



People Who Read This Also Read


Indian IT Cos struggle in China

Tribunal adjourns DPC hearing

ONGC may buy HPCL stake in MRPL




© Copyright 2003 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.








Copyright © 2003 rediff.com India Limited. All Rights Reserved.